Merck Sharp & Dohme Limited

LONDON - For Healthcare and Pharmaceutical Correspondents Only - NICE Recommends Considering DPP-4 Inhibitors as a Second Line Treatment Option in Appropriate Patients Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the UK, which recommends considering a range of newer therapy options, including 'Januvia' (sitagliptin).